# Singular Genomics Systems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/singular-genomics-systems

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.singulargenomics.com/
- Latest round: Seed (Jan 1, 2016)
- Investors on record: 1

## About

Based in California, US, and founded in 2016 by Drew Spaventa and Eli Glezer, Singular Genomics is a biotechnology company focused on providing advanced genomic sequencing technologies to enhance DNA analysis speed and accuracy, addressing critical challenges in genomics. The company is trading on the Nasdaq Global Select Market under the ticker symbol OMIC. In December 2024, Deerfield Management acquired Singular Genomics Systems, Inc. for USD 20 per share, in a public-to-private deal. Singular Genomics offers a G4 instrument that is a next-generation sequencer (NGS) to produce genetic sequencing results and an associated menu of consumable kits. In addition, the company provides PX integrated solution that combines single-cell analysis, proteomics, genomics, and spatial analysis under one integrated instrument offering multi-omics solutions. These systems are primarily utilized in research institutions, laboratories, and clinical settings, serving customers who require precision and efficiency in genomic research. The company’s solutions aim to facilitate advancements in personalized medicine, disease research, and evolutionary studies, with products designed for a global market that includes North America, Europe, and Asia. The December 2024 acquisition will enable Singular Genomics to enhance its technologies and business development. Moreover, the company plans to develop new products aimed at expanding its offerings in genomic sequencing. Additionally, Singular Genomics is targeting expansions into new markets within Europe and Asia by 2025.

## Funding rounds

- Seed, Jan 1, 2016 — Domain Associates

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Seed